The objective of this study was to prepare solid lipid microparticles (SLMs) loaded with the polar adenosine A1 receptor agonist N6-cyclopentyladenosine (CPA). The microparticles were produced by the conventional hot emulsion technique, using different lipidic carriers (tristearin, glyceryl behenate and stearic acid) and hydrogenated phosphatidylcholine as the surfactant. The controlled release of CPA was achieved only with stearic acid microparticles. This phenomenon has been attributed to direct acid-base interactions between the basic nitrogen atoms of CPA and stearic acid. These SLMs were characterized by release studies, scanning electron microscopy and powder X-ray diffraction analyses. The obtained particles showed proper featur...
The prodrug 5'-octanoyl-CPA (Oct-CPA) of the antiischemic N6-cyclopentyladenosine (CPA) has been enc...
The prodrug 5'-octanoyl-CPA (Oct-CPA) of the antiischemic N-6-cyclopentyladenosine (CPA) has been en...
Introduction : Solid lipid particles have been introduced since the early 1990s as an alternative dr...
The objective of this study was to prepare solid lipid microparticles (SLMs) loaded with the polar a...
We report a preliminary study evaluating the encapsulation modalities in microparticles of the antii...
A study concerning the feasibility of microsphere use as sustained delivery systems for N(6)-cyclope...
Ischemic tolerance and neuronal protection can be obtained by activation of adenosine A1 membrane re...
We report a preliminary study concerning the encapsulation modalities in nanoparticles of the anti-i...
Purpose: We report a study of encapsulation and release from solid lipid microparticles (SLMs) of a ...
Purpose: We report a study of encapsulation and release from solid lipid microparticles (SLMs) of a ...
The aim of the study was to evaluate the potential of using solid lipid microparticles (SLM) for the...
We report a study of encapsulation and release from polymeric micro- and nano-particles of the antii...
This review details the properties of solid lipid microparticles (SLMs): a promising drug carrier sy...
A novel non-aqueous nanoprecipitation method was proposed to achieve the encapsulation of a small we...
5-Aminosalicylic acid (5-ASA), the active moiety of sulphasalazine, is the most commonly used drug f...
The prodrug 5'-octanoyl-CPA (Oct-CPA) of the antiischemic N6-cyclopentyladenosine (CPA) has been enc...
The prodrug 5'-octanoyl-CPA (Oct-CPA) of the antiischemic N-6-cyclopentyladenosine (CPA) has been en...
Introduction : Solid lipid particles have been introduced since the early 1990s as an alternative dr...
The objective of this study was to prepare solid lipid microparticles (SLMs) loaded with the polar a...
We report a preliminary study evaluating the encapsulation modalities in microparticles of the antii...
A study concerning the feasibility of microsphere use as sustained delivery systems for N(6)-cyclope...
Ischemic tolerance and neuronal protection can be obtained by activation of adenosine A1 membrane re...
We report a preliminary study concerning the encapsulation modalities in nanoparticles of the anti-i...
Purpose: We report a study of encapsulation and release from solid lipid microparticles (SLMs) of a ...
Purpose: We report a study of encapsulation and release from solid lipid microparticles (SLMs) of a ...
The aim of the study was to evaluate the potential of using solid lipid microparticles (SLM) for the...
We report a study of encapsulation and release from polymeric micro- and nano-particles of the antii...
This review details the properties of solid lipid microparticles (SLMs): a promising drug carrier sy...
A novel non-aqueous nanoprecipitation method was proposed to achieve the encapsulation of a small we...
5-Aminosalicylic acid (5-ASA), the active moiety of sulphasalazine, is the most commonly used drug f...
The prodrug 5'-octanoyl-CPA (Oct-CPA) of the antiischemic N6-cyclopentyladenosine (CPA) has been enc...
The prodrug 5'-octanoyl-CPA (Oct-CPA) of the antiischemic N-6-cyclopentyladenosine (CPA) has been en...
Introduction : Solid lipid particles have been introduced since the early 1990s as an alternative dr...